Hsbc Holdings PLC Sells 26,119 Shares of IQVIA Holdings Inc. $IQV

Hsbc Holdings PLC reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 338,340 shares of the medical research company’s stock after selling 26,119 shares during the quarter. Hsbc Holdings PLC’s holdings in IQVIA were worth $76,303,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Brighton Jones LLC raised its position in shares of IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares during the period. Empowered Funds LLC boosted its holdings in shares of IQVIA by 102.1% during the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after buying an additional 4,915 shares during the period. Sivia Capital Partners LLC acquired a new position in IQVIA in the 2nd quarter valued at about $514,000. First Trust Advisors LP grew its stake in IQVIA by 14.8% in the 2nd quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after buying an additional 11,845 shares during the last quarter. Finally, NewEdge Advisors LLC raised its holdings in IQVIA by 5.4% in the 2nd quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after acquiring an additional 1,155 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Morgan Stanley restated an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Weiss Ratings lowered IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Wall Street Zen cut IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. HSBC set a $210.00 price target on IQVIA in a research note on Wednesday, June 3rd. Finally, Evercore reiterated an “outperform” rating and set a $185.00 price objective on shares of IQVIA in a research report on Wednesday, April 8th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $222.00.

IQVIA Stock Down 0.3%

NYSE IQV opened at $206.38 on Friday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a market cap of $34.44 billion, a price-to-earnings ratio of 25.57, a PEG ratio of 1.78 and a beta of 1.20. The company has a 50 day moving average of $176.95 and a 200-day moving average of $189.30. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $247.04.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts expect that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its board has approved a share buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.